LexDanaLexDanabeta
Inventor

Melissa Fleury

Inventor
Brisbane, CA, US

Overview

78→
Patents
2010–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 78 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C07DHeterocyclic compounds24%
A61KPreparations for medical, dental or toiletry purposes24%
C07CAcyclic or carbocyclic compounds12%
C07BGeneral methods of organic chemistry6%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
C30BSingle-crystal growth2%
Y02PClimate change mitigation technologies in the production or processing of goods1%
A01NPreservation of bodies of humans or animals or plants or parts thereof1%
C09KMaterials for miscellaneous applications, not provided for elsewhere1%
PatentTitleYear
11,046,6912-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors202111,033,533(2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid202110,836,744Diamide compounds having muscarinic receptor antagonist and b2 adrenergic receptor agonist activity202010,829,438Neprilysin inhibitors202010,752,599Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof202010,744,104Neprilysin inhibitors202010,590,107Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity202010,570,120Neprilysin inhibitors202010,548,879(2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid202010,526,330JAK kinase inhibitor compounds for treatment of respiratory disease202010,472,335Crystalline(2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof201910,358,433Diamide compounds having muscarinic receptor antagonist and b2 adrenergic receptor agonist activity201910,315,984Neprilysin inhibitors201910,189,823Neprilysin inhibitors201910,172,834(2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid201910,138,220Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity201810,130,642Neprilysin inhibitors201810,123,984Neprilysin inhibitors201810,100,021Crystalline(2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof201810,100,049JAK kinase inhibitor compounds for treatment of respiratory disease201810,053,417Neprilysin inhibitors201810,028,960Pyrimidine compounds as JAK kinase inhibitors201810,005,740Neprilysin inhibitors20189,981,999Neprilysin inhibitors20189,975,875Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity20189,884,807'Neprilysin inhibitors'20189,872,855(2R,4R)-5-(5'-Chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid20189,873,685Neprilysin inhibitors20189,868,698'(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid'20189,845,332Neprilysin inhibitors20179,839,639'Neprilysin inhibitors'20179,840,460'Neprilysin inhibitors'20179,783,507'Neprilysin inhibitors'20179,771,337'Neprilysin inhibitors'20179,771,350'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,725,470'Substituted naphthyridines as JAK kinase inhibitors'20179,725,448'Neprilysin inhibitors'20179,724,359'Neprilysin inhibitors'20179,688,616'Neprilysin inhibitors'20179,688,692'Neprilysin inhibitors'20179,682,052'Neprilysin inhibitors'20179,683,002'Neprilysin inhibitors'20179,682,957'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,670,143'(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acid'20179,670,186'Neprilysin inhibitors'20179,593,110'Neprilysin inhibitors'20179,585,882'Neprilysin inhibitors'20179,572,802'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20179,555,041'Neprilysin inhibitors'20179,533,962'(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid'20179,499,487'Neprilysin inhibitors'20169,487,514'Neprilysin inhibitors'20169,433,598'(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid'20169,428,457'Neprilysin inhibitors'20169,388,145'Neprilysin inhibitors'20169,334,245'Neprilysin inhibitors'20169,150,500'Neprilysin inhibitors'20159,126,956'Neprilysin inhibitors'20159,120,758'Neprilysin inhibitors'20159,120,747'Neprilysin inhibitors'20159,108,934'Neprilysin inhibitors'20159,096,496'Neprilysin inhibitors'20158,901,169'Neprilysin inhibitors'20148,871,792'Neprilysin inhibitors'20148,853,427'Neprilysin inhibitors'20148,846,913'Neprilysin inhibitors'20148,822,522'Dual-acting pyrazole antihypertensive agents'20148,691,868'Neprilysin inhibitors'20148,686,184'Neprilysin inhibitors'20148,586,536'Neprilysin inhibitors'20138,563,512'Neprilysin inhibitors'20138,481,044'Neprilysin inhibitors'20138,449,890'Neprilysin inhibitors'20138,350,027'Dual-acting pyrazole antihypertensive agents'20138,138,345'Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity'20128,119,634'Dual-acting pyrazole antihypertensive agents'20127,956,054'Dual-acting pyrazole antihypertensive agents'20117,642,339'Antiviral compounds'2010

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2010Based in Redwood City, CA, US· patent location history
2011–2017Based in San Francisco, CA, US· patent location history
2012–2017Patents assigned to FLEURY MELISSA (29)· patent assignee history
2012–2017Patents assigned to GENDRON ROLAND (19)· patent assignee history
2012Based in San Mateo, CA, US· patent location history
2013–2017Patents assigned to HUGHES ADAM D (25)· patent assignee history
2014–2015Patents assigned to THERAVANCE BIOPHARMA R & D IP LLC (11)· patent assignee history
2015–2021Based in Brisbane, CA, US· patent location history
2016–2021Patents assigned to THERAVANCE BIOPHARMA R&D IP LLC (46)· patent assignee history
2021Based in South San Francisco, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
THERAVANCE BIOPHARMA R&D IP LLC462016–2021
FLEURY MELISSAself292012–2017
HUGHES ADAM D252013–2017
GENDRON ROLAND192012–2017
THERAVANCE BIOPHARMA R & D IP LLC112014–2015
Locations
LocationPatentsSpan
Brisbane, California, US522015–2021
San Francisco, California, US232011–2017
South San Francisco, California, US12021
San Mateo, California, US12012
Redwood City, California, US12010